Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

5.080 USD -0.370 (-6.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,187,183
Open 5.070
Bid (Size) 5.040 (3)
Ask (Size) 5.050 (20)
Prev. Close 5.450
Today's Range 4.655 - 5.220
52wk Range 4.000 - 15.65
Shares Outstanding 61,930,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new data from the dose-escalation portion of the... 
From Business Wire News Releases
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of... 
From Business Wire News Releases

Performance

YTD
-52.66%
-52.66%
1 Month
+20.09%
+20.09%
3 Month
-0.39%
-0.39%
6 Month
-46.01%
-46.01%
1 Year
-49.80%
-49.80%

More News

Read More
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
From Business Wire News Releases
Syros to Present at Upcoming Investor Conferences in September
From Business Wire News Releases
12 Health Care Stocks Moving In Friday's Intraday Session
Tags PTGX Market News Benzinga
From Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Tags SYRS Pre/Market Outlook AVTX
From Benzinga
Analysts Anticipate IBB To Hit $199
Tags ETFs
From ETF Channel
Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
From Business Wire News Releases
Looking Into Syros Pharmaceuticals's Return On Capital Employed
Tags Market News Earnings Benzinga
From Benzinga
Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
From Business Wire News Releases
Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.